Fat accumulation in the body has been implicated in the increased generation of ROS and oxidative stress which enhances hepatocellular damage. Increase in serum liver enzymes have been widely used as an index of liver dysfunction and that higher ALT concentrations predicted development of type 2 diabetes. Thirty rabbits were randomly divided into six groups, each of five animals: Group 1 = control (C), Group 2 = cholesterol diet (CD) only, Group 3 = resveratrol 200 mg/kg (R200), Group 4 = resveratrol 400 mg/kg (R400), Group 5 = CD + R200 and group 6 = CD + R400. The preparations were administered for 8 weeks of experimental protocol. Blood glucose level was measured on week zero and the 8th week of the treatment. At the end of the study period, the rabbits were placed under light anesthesia (ketamine) to remain unconscious. Blood sample of about 3ml was drawn via cardiac puncture for serum extraction which were evaluated for serum concentration of liver enzymes (alanine aminotransferase ALT, aspartate aminotransferase AST and alkaline phosphatase ALP) and oxidative stress biomarkers (superoxide dismutase SOD, catalase CAT and glutathione peroxidase GPx). Blood glucose level was significantly higher in CD group compared to groups that received resveratrol supplement. Serum Liver enzymes activities showed significant (P < 0.05) decrease in ALT, AST and ALP levels in groups that were administered resveratrol with CD compared with CD alone. Significant decrease in antioxidant enzymes activities (SOD, CAT and GPx) in resveratrol treated groups (P < 0.05) were recorded when compared to CD alone group. In conclusion, the observed decreased in blood glucose level, liver enzymes and biomarkers of oxidative stress with resveratrol administration despite CD consumptions, elucidated the therapeutic potential of resveratrol.Support or Funding Information1. SelfThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.